| | | | | Moderna Inc said on Monday it has started a U.S. government-backed late-stage trial to assess its COVID-19 vaccine candidate in about 30,000 adults who do not have the respiratory illness caused by the new coronavirus. | | |
| | | The United States might have more COVID-19 testing capacity than any other country. So why have we seen laboratories overwhelmed and many patients again waiting a week or more for results? | | |
| | | U.S. President Donald Trump on Friday signed four executive orders designed to reduce drug costs for consumers, in a bid to highlight his commitment to cutting prescription prices ahead of the November presidential election. | | |
| | | The new coronavirus pandemic that has infected more than 16 million people is easily the worst global health emergency the World Health Organization (WHO) has faced, its director general Tedros Adhanom Ghebreyesus said on Monday. | | |
| | | Emergent BioSolutions Inc said on Monday it signed a $174 million agreement with AstraZeneca to develop and manufacture the British drugmaker's COVID-19 vaccine candidate. | | |
| | | Evidence emerging around the world suggests that people who are overweight or obese are at increased risk of getting more severely ill with COVID-19, the disease caused by the SARS-CoV2 coronavirus. | | |
| | | Here's what you need to know about the coronavirus right now: | | |
| | | Indonesia reported on Monday its total number of coronavirus cases had topped 100,000, as the president urged officials handling the outbreak to retain an "aura of crisis" in a country with the most infections and deaths in East Asia. | | |
| | | India's chemicals minister on Monday outlined plans to boost local manufacturing in the bulk drugs and medical device industries to reduce India's reliance on imports, particularly from China. | | |
| | | Zebra Medical Vision, an Israeli medical imaging analytics company, said on Monday it received clearance from the U.S. Food and Drug Administration for its mammography technology. | | |
| | | Britain's AstraZeneca will pay up to $6 billion to Japan's Daiichi Sankyo under the drugmakers' second multi-billion dollar oncology collaboration to develop and market a niche type of targeted cancer treatment. | | |
|
| |
